Inventiva Announces Positive Topline Results From the Investigator-Initiated Phase II Clinical Trial Evaluating Lanifibranor in Patients with T2D and NAFLD

Lanifibranor 800mg achieved the primary efficacy endpoint demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance spectroscopy (1H-MRS) following 24 weeks of treatment in patients with nonalcoholic fatty liver disease...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials